Biostar Pharmaceuticals, Inc.
BSPM
BSPM was delisted on the 18th of September, 2018.
6 hedge funds and large institutions have $305K invested in Biostar Pharmaceuticals, Inc. in 2018 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 0 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
50% more funds holding
Funds holding: 4 → 6 (+2)
9% less capital invested
Capital invested by funds: $335K → $305K (-$30K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
+$45.8K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$15K |
| 3 |
Morgan Stanley
New York
|
+$9.82K |
| 4 |
IA
IFP Advisors
Tampa,
Florida
|
+$8.13K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$7.76K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$1.72K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Acadian Asset Management
Boston,
Massachusetts
| $239K | +$15K | +6,001 | +6% |
|
|
2
Barclays
London,
United Kingdom
| $41K | +$45.8K | +18,300 | New |
|
|
3
Morgan Stanley
New York
| $9K | +$9.82K | +3,926 | +16,358% |
|
|
4
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $8K | +$7.76K | +3,100 | +775% |
|
|
IA
5
IFP Advisors
Tampa,
Florida
| $7K | +$8.13K | +3,250 | New |
|
|
6
UBS Group
Zurich,
Switzerland
| $1K | -$1.72K | -689 | -70% |
|
BSPM Hedge Fund Activity: Q2 2018 in Review
6 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Biostar Pharmaceuticals, Inc. (BSPM) for Q2 2018, worth a combined $305K — down 9% from $335K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new BSPM positions and 0 closed out — a net gain of 2 holders — while 3 added to existing stakes and 1 trimmed.
The largest buyer was Barclays, opening a new position worth an estimated $45.8K. The largest seller was UBS Group, cutting an estimated $1.72K.
- 6 institutional investors held Biostar Pharmaceuticals, Inc. (BSPM) as of Q2 2018, up from 4 in Q1 2018.
- Funds reported $305K of Biostar Pharmaceuticals, Inc. stock for Q2 2018, down 9% quarter-over-quarter.
- 2 funds opened new Biostar Pharmaceuticals, Inc. positions in Q2 2018 and 0 closed out, a net change of +2 holders.
- The largest Biostar Pharmaceuticals, Inc. buyer in Q2 2018 was Barclays, an estimated $45.8K added.
- The largest Biostar Pharmaceuticals, Inc. seller in Q2 2018 was UBS Group, an estimated $1.72K sold.
Based on aggregated 13F filings for Q2 2018.